Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine

NCT00006114 is registered in ClinicalTrials.gov with GERCOR - Multidisciplinary Oncology Cooperative Group as lead sponsor.

NCT NCT00006114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 1999
Completion date
Not reported
Enrollment
Not reported
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer